Research
Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial
The Brief
- Tirzepatide (Zepbound) produced substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications.
- The results come from the phase III SURMOUNT-ADOLESCENTS trial.
- The findings were reported at ObesityWeek in National Harbor, Md.
Why it matters
The phase III trial provides evidence on BMI outcomes of tirzepatide in adolescents, a population with fewer treatment studies than adults.
Who’s affected
- clinicians treating adolescents with obesity
- adolescents with obesity and their families
- #tirzepatide
- #obesity
- #adolescents
- #clinical trial
- #bmi
- #weight management
(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...